Browsing by Author "Papakostas, George"
Now showing items 1-4 of 4
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY)
Fava, Maurizio; Dirks, Bryan; Shelton, Richard C.; Thase, Michael E.; Trivedi, Madhukar H.; Liu, Keith; Stankovic, Srdjan; Freeman, Marlene; Papakostas, George (Physicians Postgraduate Press, Inc, 2019-09-24)Objective: Pimavanserin is a 5-hydroxytryptamine2A antagonist/inverse receptor agonist. In this Phase 2 study, we studied the efficacy and safety of pimavanserin as adjunctive therapy in patients with major depressive ... -
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder
Baek, Ji Hyun; Kim, Hee-Jin; Fava, Maurizio; Mischoulon, David; Papakostas, George I; Nierenberg, Andrew; Heo, Jung-Yoon; Jeon, Hong Jin (Korean Neuropsychiatric Association, 2016)Objective: Anxious depression has a distinct neurobiology, clinical course and treatment response from non-anxious depression. Role of inflammation in anxious depression has not been examined. As an exploratory study to ... -
Residual Sleep Disturbance and Risk of Relapse During the Continuation/Maintenance Phase Treatment of Major Depressive Disorder with the Selective Serotonin Reuptake Inhibitor Fluoxetine
Yang, Huaiyu; Sinicropi-Yao, Lara; Chuzi, Sarah; Youn, Soo Jeong; Clain, Alisabet; Baer, Lee; Chen, Ying; McGrath, Patrick J; Fava, Maurizio; Papakostas, George I (BioMed Central, 2010)Background: Relapse of major depressive disorder (MDD) is a common clinical problem. This study was designed to determine whether residual sleep disturbance (insomnia and hypersomnia) predict risk of relapse during the ... -
Success and Efficiency of Phase 2/3 Adjunctive Trials for MDD Funded by Industry: A Systematic Review
Salloum, Naji; Papakostas, George; Fava, Maurizio; Ball, Sophia; Ball, Sophia (2020-01-27)To review the success rate and efficiency of industry-sponsored phase 2/3 clinical trials for adjunctive therapies for antidepressant partial- and non-responders with major depressive disorder (MDD), a systematic search ...